Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Growth in Short Interest

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 72,100 shares, an increase of 281.5% from the January 31st total of 18,900 shares. Approximately 2.6% of the company’s shares are sold short. Based on an average daily volume of 42,900 shares, the days-to-cover ratio is presently 1.7 days.

Kiora Pharmaceuticals Trading Down 3.0 %

NASDAQ KPRX traded down $0.10 during trading hours on Friday, hitting $3.25. 13,781 shares of the stock were exchanged, compared to its average volume of 41,802. Kiora Pharmaceuticals has a 12-month low of $3.00 and a 12-month high of $6.48. The stock has a 50-day moving average of $3.59 and a 200 day moving average of $3.54.

Institutional Trading of Kiora Pharmaceuticals

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC lifted its holdings in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,221 shares of the company’s stock after acquiring an additional 3,670 shares during the quarter. ADAR1 Capital Management LLC owned about 6.67% of Kiora Pharmaceuticals worth $661,000 as of its most recent filing with the Securities and Exchange Commission. 76.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Kiora Pharmaceuticals in a report on Tuesday, November 12th.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.